{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:01:55Z","timestamp":1763755315125,"version":"3.45.0"},"reference-count":12,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJON"],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1188\/16.cjon.602-604","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T07:51:10Z","timestamp":1479455470000},"page":"602-604","source":"Crossref","is-referenced-by-count":1,"title":["Minimizing Hazards Associated With Live-Virus Immunotherapeutic Cancer Vaccines"],"prefix":"10.1188","volume":"20","author":[{"given":"Sheri","family":"McMahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"1","unstructured":"Centers for Disease Control and Prevention. (2009). Biosafety in microbiological and biomedical laboratories (BMBL) (5th ed.). Retrieved from https:\/\/www.cdc.gov\/biosafety\/publications\/bmbl5\/bmbl.pdf"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Geary, S.M., & Salem, A.K. (2013). Prostate cancer vaccines: Update on clinical development. Oncoimmunology, 2, e24523. doi:10.4161\/onci.24523","DOI":"10.4161\/onci.24523"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Gilbert, S.C. (2013). Clinical development of modified vaccinia virus ankara vaccines. Vaccine, 31, 4241\u20134246.","DOI":"10.1016\/j.vaccine.2013.03.020"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Gulley, J.L., Arlen, P.M., Madan, R.A., Tsang, K.Y., Pazdur, M.P., Skarupa, L., . . . Schlom, J. (2010). Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunology, Immunotherapy, 59, 663\u2013674. doi:10.1007\/s00262-009-0782-8","DOI":"10.1007\/s00262-009-0782-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Gulley, J.L., Madan, R.A., Tsang, K.Y., Jochems, C., Mart\u00e9, J.L., Farsaci, B., . . . Schlom, J. (2014). Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunology Research, 2, 133\u2013141.","DOI":"10.1158\/2326-6066.CIR-13-0108"},{"key":"6","unstructured":"Kim, J.W., Marte, J.L., Singh, N.K., Heery, C.R., Madan, R.A., Pazdur, M., . . . Gulley, J.L. (2013). Safety profile of recombinant poxviral TRICOM vaccines [Abstract e16036]. Retrieved from http:\/\/meetinglibrary.asco.org\/content\/115479-132"},{"key":"7","unstructured":"National Cancer Institute. (2015). Cancer vaccines. Retrieved from http:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/vaccines-fact-sheet"},{"key":"8","unstructured":"Rotz, L.D., Dotson, D.A., Damon, I.K., & Becher, J.A. (2001). Vaccinia (smallpox) vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. Retrieved from http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5010a1.htm"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Sepkowitz, K.A. (2003). How contagious is vaccinia? New England Journal of Medicine, 348, 439\u2013446. doi:10.1056\/NEJMra022500","DOI":"10.1056\/NEJMra022500"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Singh, P., Pal, S.K., Alex, A., & Agarwal, N. (2015). Development of PROSTVAC immunotherapy in prostate cancer. Future Oncology, 11, 2137\u20132148. doi:10.2217\/fon.15.120","DOI":"10.2217\/fon.15.120"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Talbot, T.R., Peters, J., Yan, L., Wright, P.F., & Edwards, K.M. (2006). Optimal bandaging of smallpox vaccination sites to decrease the potential for secondary vaccinia transmission without impairing lesion healing. Infection Control and Hospital Epidemiology, 27, 1184\u20131192. doi:10.1086\/508827","DOI":"10.1086\/508827"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Wong, K.K., Li, W.A., Mooney, D.J., & Dranoff, G. (2016). Advances in therapeutic cancer vaccines. Advances in Immunology, 130, 191\u2013249.","DOI":"10.1016\/bs.ai.2015.12.001"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/cjon.ons.org\/cjon\/20\/6\/minimizing-hazards-associated-live-virus-immunotherapeutic-cancer-vaccines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:20Z","timestamp":1763754740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/20\/6\/minimizing-hazards-associated-live-virus-immunotherapeutic-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.cjon.602-604","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2016,12,1]]}}}